Skip to content
Procarbazine hydrochloride
Matulane (procarbazine hydrochloride) is a small molecule pharmaceutical. Procarbazine hydrochloride was first approved as Matulane on 1982-01-01. It is used to treat brain neoplasms, hodgkin disease, lung neoplasms, melanoma, and multiple myeloma amongst others in the USA.
Download report
Favorite
Drugs Approved for Childhood Cancers
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
respiratory tract diseasesD012140
nervous system diseasesD009422
cardiovascular diseasesD002318
hemic and lymphatic diseasesD006425
immune system diseasesD007154
Trade Name
FDA
EMA
Matulane
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Procarbazine hydrochloride
Tradename
Company
Number
Date
Products
MATULANELeadiant BiosciencesN-016785 RX1982-01-01
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
matulaneNew Drug Application2020-11-19
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
brain neoplasmsEFO_0003833D001932C71
hodgkin disease—D006689C81
lung neoplasms—D008175C34.90
melanoma—D008545—
multiple myeloma—D009101C90.0
non-hodgkin lymphoma—D008228C85.9
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01X: Other antineoplastic agents in atc
— L01XB: Methylhydrazines, antineoplastics
— L01XB01: Procarbazine
HCPCS
Code
Description
S0182
Procarbazine hydrochloride, oral, 50 mg
Clinical
Clinical Trials
63 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LymphomaD008223C85.91177—328
Central nervous system neoplasmsD016543369——16
Hodgkin diseaseD006689C81—45—110
Brain neoplasmsD001932EFO_0003833C71—11——2
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-hodgkin lymphomaD008228C85.9—1———1
GlioblastomaD005909EFO_0000515—1———1
Aids-related lymphomaD016483EFO_1001365—1———1
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Ataxia telangiectasiaD001260Orphanet_100G11.3————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePROCARBAZINE HYDROCHLORIDE
INNprocarbazine
Description
Procarbazine is a benzamide obtained by formal condensation of the carboxy group of 4-[(2-methylhydrazino)methyl]benzoic acid with the amino group of isopropylamine. An antineoplastic chemotherapy drug used for treatment of Hodgkin's lymphoma. Metabolism yields azo-procarbazine and hydrogen peroxide, which results in the breaking of DNA strands. It has a role as an antineoplastic agent. It is a member of hydrazines and a member of benzamides. It is a conjugate base of a procarbazine(1+).
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CNNCc1ccc(C(=O)NC(C)C)cc1.Cl
Identifiers
PDB—
CAS-ID366-70-1
RxCUI8702
ChEMBL IDCHEMBL1200410
ChEBI ID71428
PubChem CID4915
DrugBankDB01168
UNII ID35S93Y190K (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 5,860 documents
View more details
Safety
Black-box Warning
Black-box warning for: Matulane
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
52,562 adverse events reported
View more details